[go: up one dir, main page]

ZA985762B - Screening methods using an atpase protein from a virus of the flaviviridae family - Google Patents

Screening methods using an atpase protein from a virus of the flaviviridae family

Info

Publication number
ZA985762B
ZA985762B ZA985762A ZA985762A ZA985762B ZA 985762 B ZA985762 B ZA 985762B ZA 985762 A ZA985762 A ZA 985762A ZA 985762 A ZA985762 A ZA 985762A ZA 985762 B ZA985762 B ZA 985762B
Authority
ZA
South Africa
Prior art keywords
virus
screening methods
flaviviridae family
atpase protein
atpase
Prior art date
Application number
ZA985762A
Other languages
English (en)
Inventor
Alfred Delvecchio
Weidong Zhong
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of ZA985762B publication Critical patent/ZA985762B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/706Specific hybridization probes for hepatitis
    • C12Q1/707Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Enzymes And Modification Thereof (AREA)
ZA985762A 1997-07-02 1998-07-01 Screening methods using an atpase protein from a virus of the flaviviridae family ZA985762B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5158297P 1997-07-02 1997-07-02

Publications (1)

Publication Number Publication Date
ZA985762B true ZA985762B (en) 1999-01-19

Family

ID=21972179

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA985762A ZA985762B (en) 1997-07-02 1998-07-01 Screening methods using an atpase protein from a virus of the flaviviridae family

Country Status (8)

Country Link
US (1) US6010848A (xx)
EP (1) EP0998585B1 (xx)
JP (1) JP2002511763A (xx)
AU (1) AU8180598A (xx)
CA (1) CA2289453A1 (xx)
DE (1) DE69838328T2 (xx)
WO (1) WO1999001582A1 (xx)
ZA (1) ZA985762B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140330B1 (en) * 1998-11-23 2005-04-06 Zenon Environmental Inc. Water filtration using immersed membranes
US7166475B2 (en) * 1999-02-26 2007-01-23 Cyclacel Ltd. Compositions and methods for monitoring the modification state of a pair of polypeptides
US6540996B1 (en) * 1999-04-15 2003-04-01 Devgen Nv Compound screening methods
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
JP4733023B2 (ja) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニー C型肝炎ウイルスの大環状イソキノリンペプチド阻害剤
US7582428B2 (en) 2003-08-22 2009-09-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-HCV agents
TWI294036B (en) * 2005-02-24 2008-03-01 Tzu Chi Buddhist General Hospital A method for screening compounds against flaviviruses infection by using persistent virus-infected cell systems
US8455227B2 (en) * 2005-06-15 2013-06-04 The Trustees Of The University Of Pennsylvania Detection of HIV-1 infection
WO2008073165A2 (en) 2006-08-25 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-hcv agents
US20100093018A1 (en) * 2007-04-26 2010-04-15 Achillion Pharmaceuticals, Inc. Cells expressing chimeric proteins and assays using such cells
WO2009005615A1 (en) 2007-06-27 2009-01-08 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying agents that inhibit an ns4b-mediated neoplastic cellular phenotype of hcv infected cells
AU2009322400A1 (en) 2008-12-03 2011-06-30 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
JP5762971B2 (ja) 2008-12-03 2015-08-12 プレシディオ ファーマシューティカルズ インコーポレイテッド Hcvns5aの阻害剤
MX2011010132A (es) 2009-03-27 2011-10-14 Presidio Pharmaceuticals Inc Inhibidores de anillo fusionado de hepatitis c.
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
WO2012020036A1 (en) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Hepatitis c virus inhibitors
WO2012123298A1 (en) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Antiviral compounds
WO2012175581A1 (en) 2011-06-24 2012-12-27 F. Hoffmann-La Roche Ag Antiviral compounds
MX2014003705A (es) 2011-10-10 2014-07-22 Hoffmann La Roche Compuestos antivirales.
MX2014006745A (es) 2011-12-16 2014-10-15 Hoffmann La Roche Inhibidores de hcv ns5a.
KR101687084B1 (ko) 2011-12-20 2016-12-15 리보사이언스 엘엘씨 Hcv rna 복제의 억제제로서 4'-아지도, 3'-플루오로 치환된 뉴클레오시드 유도체
UA111761C2 (uk) 2011-12-20 2016-06-10 Рібосаєнс Ллс 2',4'-дифтор-2'-метилзаміщені нуклеозидні похідні як інгібітори реплікації phk вірусу гепатиту c
BR112014015582A8 (pt) 2012-02-24 2017-07-04 Hoffmann La Roche compostos antivirais
US20140010783A1 (en) 2012-07-06 2014-01-09 Hoffmann-La Roche Inc. Antiviral compounds
RU2015132550A (ru) 2013-01-23 2017-03-02 Ф. Хоффманн-Ля Рош Аг Противовирусные производные триазола
WO2014135422A1 (en) 2013-03-05 2014-09-12 F. Hoffmann-La Roche Ag Antiviral compounds
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
US9895442B2 (en) 2013-05-16 2018-02-20 Riboscience Llc 4′-fluoro-2′-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
BR112015028765A2 (pt) 2013-05-16 2017-07-25 Riboscience Llc derivados de nucleosídeo substituído 4'-azido, 3'-desoxi-3'-fluoro
SG11202002431SA (en) 2017-09-21 2020-04-29 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0318216B2 (en) * 1987-11-18 2001-08-29 Chiron Corporation NANBV diagnostics
US5945425A (en) * 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease

Also Published As

Publication number Publication date
AU8180598A (en) 1999-01-25
US6010848A (en) 2000-01-04
DE69838328T2 (de) 2008-05-21
CA2289453A1 (en) 1999-01-14
DE69838328D1 (de) 2007-10-11
EP0998585A4 (en) 2004-11-10
WO1999001582A1 (en) 1999-01-14
EP0998585B1 (en) 2007-08-29
EP0998585A1 (en) 2000-05-10
JP2002511763A (ja) 2002-04-16

Similar Documents

Publication Publication Date Title
ZA985762B (en) Screening methods using an atpase protein from a virus of the flaviviridae family
PL336420A1 (en) Improved methods of processing activated protein c
ID24201A (id) Rekoveri komponen-komponen limbah kulit telur
FR2770899B1 (fr) Microgyrometre vibrant
ZA9811316B (en) Novel hepatitis C virus NS5B protein
IL137952A0 (en) Method for designing dna-binding proteins of the zinc-finger class
IL171896A0 (en) Fusion protein comprising a hcv ns3 helicase fragment
IL136465A0 (en) Architecture for an application framework
DE69834986D1 (de) Toner und Bildherstellungsverfahren
NO20011843D0 (no) Selektivt replikerende virusvektorer
IL146743A0 (en) Screening method for peptides
DE69833039D1 (de) Trennprozess
EP1038037A4 (en) DETERMINATION PROCEDURE FOR DETECTING AND DIAGNOSING THE INFLUENCE VIRUS
DE19581726T1 (de) Horizontal vibrierende Zentrifuge
IT1288107B1 (it) Calotta schermante
GB2324224B (en) Method of call screening
HUP0003511A3 (en) Hepatitis b virus polypeptides
IL141523A0 (en) High-affinity antibodies
EP1140121A4 (en) CRYOGRANULATION OF ACTIVATED PROTEIN C
HK1028792A (en) Screening methods using an atpase protein from a virus of the flaviviridae family
DE69916516D1 (de) Schwingsieb
GB9702990D0 (en) Virus vaccine
GB9713667D0 (en) Enhancement of intestinal permeability
ATA84697A (de) Siebrechen
GB9706078D0 (en) Screening method and proteins and dna identified thereby